2 Pharma Stocks in the Middle of an Oncology Sales Explosion

Global spending on cancer drugs has soared in recent years along with the number of expensive new treatments reaching patients in need of new options. Roche (NASDAQOTH: RHHBY) led the industry with around $26 billion in oncology sales last year, but losses from aging brands will soon push the Swiss pharmaceutical giant out of the top spot.